PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
JW Shinyak has recovered from a large net loss in 2023 to clearly improving profits in 2024 and 2025, even as revenue has contracted for three straight years.
2025 consolidated revenue was KRW 81.0bn (down year-on-year), operating profit KRW 7.46bn, and owners' net profit KRW 15.66bn, with profit rising sharply
The debt ratio fell sharply from 299% in 2023 to 43% in 2025, indicating improved financial structure
Over the trailing four quarters (2025Q3-2026Q2), revenue rose modestly each quarter, with 2026Q2 operating profit of KRW 3.58bn the highest in that window
A sales network specialized in clinic-level markets—dermatology, urology, and ENT—is a core competitive strength
If affiliate JW Pharma's hair-loss drug candidate 'JW0061' succeeds, there is potential for group synergy such as joint clinic-level marketing
JW Shinyak's core business is the manufacture and sale of pharmaceuticals, primarily antifungal agents and urology drugs supplied to clinic and internal medicine markets.
The company entered the clinic market following the 2000 separation of prescribing and dispensing, growing into a specialist supplier to dermatology, urology, pediatric, and ENT clinics, and from 2017 restructured its portfolio around internal medicine items.
Key products include the antifungal agents Heutrazole and Wonflucap, and the dermatological treatment PD Tab, through which the company has maintained sales in specialized dermatology and urology markets.
More recently, it has developed topical hair-loss treatments using lipid nanoparticle and microbubble delivery technologies, expanding into hair-care and cosmeceutical segments to strengthen competitiveness.
At the group level, affiliate JW Pharmaceutical focuses on hospital-level sales, original drugs, and innovative drug R&D with global licensing, while JW Shinyak concentrates on supplying generics and specialty products to clinic-level markets.
In hair loss, the two companies' businesses partially overlap but are structured to be complementary: JW Pharmaceutical handles contract manufacturing of finasteride/dutasteride products and develops a new-mechanism candidate, while JW Shinyak directly produces minoxidil-based products and expands sales through clinic channels.
JW Shinyak already co-markets JW Pharmaceutical's original product Livalo, indicating an existing collaboration framework between affiliates.
Through subsidiary JW Creagene, the company also pursues next-generation cell therapy research including CAR-M and CAR-NK, and in December 2023 signed a joint research agreement with U.S.-based KURE.AI for CAR-NK-based cell therapy development.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩19.7B | ₩2.7B | 13.5% |
| 2025Q3 | ₩20.6B | ₩2.7B | 13.1% |
| 2025Q4 | ₩21.1B | ₩1.4B | 6.7% |
| 2026Q1 | ₩21.4B | ₩2.9B | 13.5% |
| 2026Q2 | ₩21.5B | ₩3.6B | 16.6% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩102.7B | ₩4.3B | ₩1.4B | 4.2% | 2.5% | 69.0% |
| 2023 | ₩104.2B | ₩5.6B | -₩37.4B | 5.4% | −222.8% | 299.0% |
| 2024 | ₩93B | ₩10B | ₩5.1B | 10.7% | 18.9% | 137.2% |
| 2025 | ₩81B | ₩7.5B | ₩15.7B | 9.2% | 38.4% | 43.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-24
Annual revenue moved from KRW 102.7bn in 2022 and KRW 104.2bn in 2023 to KRW 93.0bn in 2024 and KRW 81.0bn in 2025, contracting for three consecutive years.
In contrast, owners' net profit swung from KRW 1.40bn in 2022 to a large loss of KRW -37.36bn in 2023, before turning positive again at KRW 5.08bn in 2024 and expanding to KRW 15.66bn in 2025—an opposing trajectory to the top line.
Operating margin improved from 4.2% in 2022 to 5.4% in 2023 and 10.7% in 2024, before easing slightly to 9.2% in 2025 as revenue declined. The debt ratio fell sharply from a high 299.0% in 2023 to 137.2% in 2024 and 43.0% in 2025, while owners' equity was rebuilt from KRW 16.77bn in 2023 to KRW 40.73bn in 2025.
On a quarterly basis, revenue rose modestly from KRW 19.70bn with operating profit of KRW 2.67bn in 2025Q2 to KRW 20.59bn and KRW 2.70bn in 2025Q3, before operating profit noticeably slowed to KRW 1.42bn in 2025Q4.
It then improved for two straight quarters, reaching KRW 21.38bn revenue and KRW 2.88bn operating profit in 2026Q1 and KRW 21.54bn revenue and KRW 3.58bn operating profit in 2026Q2, the highest operating profit within the trailing four-quarter window (2025Q3-2026Q2).
Owners' net profit also fluctuated more than operating profit across quarters, from KRW 1.98bn in 2025Q3 to KRW 3.57bn in 2026Q2, suggesting a meaningful contribution from non-operating items.
Overall, the period reflects a phase where cost efficiency and balance-sheet repair combined to improve both earnings quality and financial stability even as revenue scale shrank.
The clinic-focused pharma segment in which JW Shinyak operates primarily serves dermatology, urology, ENT, and internal medicine clinics, forming a competitive landscape distinct from the original-drug market centered on large general hospitals.
Product categories with a high share of generics, such as antifungals and urology drugs, are continuously exposed to government drug-pricing cuts and price competition among generics, requiring ongoing sales-network management and new product launches to sustain revenue scale.
The hair-loss treatment and cosmeceutical market, by contrast, continues to grow amid an aging population and rising interest in aesthetics, drawing competitive entry from numerous domestic pharma and cosmetics companies.
JW Shinyak addresses this market by directly producing minoxidil-based products and leveraging its clinic-channel sales capability, while sharing roles with affiliate JW Pharmaceutical, which handles finasteride/dutasteride contract manufacturing and development of a new-mechanism candidate.
The introduction of new pipeline assets at group affiliate JW Pharmaceutical—such as the GLP-1 class obesity treatment vopanglutide, for which domestic rights were secured through an $85 million contract—is not a business JW Shinyak is directly involved in, but it can be viewed as a factor that leaves room for future participation, such as joint marketing, given JW Shinyak's clinic sales network.
Competitors include numerous domestic small and mid-sized pharmaceutical companies with similar clinic- and generic-focused business models, and relationships with large pharma companies holding original drugs tend to take the form of collaboration, such as co-marketing, rather than direct competition.
On its own, the company is working to maintain sales of existing clinic-specialty items such as antifungals and dermatological treatments while diversifying its hair-loss treatment portfolio to maximize sales performance.
At the group level, if affiliate JW Pharmaceutical's Wnt-targeted hair-loss drug candidate 'JW0061,' currently under development, succeeds, a role division is expected in which JW Pharmaceutical handles hospital-level sales and global commercialization including overseas licensing, while JW Shinyak takes charge of co-marketing in the clinic-level market where it holds strength.
However, this depends on the clinical outcomes of a candidate being developed in-house by JW Pharmaceutical, and it should be noted that the program remains at an early stage requiring multiple clinical steps before commercialization.
Research into CAR-M and CAR-NK cell therapies through subsidiary JW Creagene is proceeding based on a joint research agreement signed with U.S.-based KURE.AI in late 2023, and progress on this research will need to be confirmed through future disclosures.
The gradual revenue increase and operating-profit improvement over two consecutive quarters in 2026Q1 and 2026Q2, following a trough in 2025Q4, over the trailing four quarters indicates a short-term earnings trend, but annual revenue remains on a declining trend, so whether this translates into an annual earnings rebound will require confirmation from additional quarterly results.
On the balance-sheet side, the sharp reduction in the debt ratio and the rebuilding of total equity could form a basis for future investment or shareholder-return capacity.
The company's profit scale has moved in a clearly recovering direction from the large net loss in 2023 through 2024 and 2025, and the valuation multiples the market assigns appear to have shifted in line with this earnings trajectory.
The share price level relative to net assets has moved within a range consistent with the multi-year trading band, which can be interpreted as reflecting the equity rebuilding that accompanied the profit recovery.
On the dividend side, no separate cash dividend has been confirmed for the most recent fiscal year, suggesting the company has prioritized balance-sheet repair and profit accumulation over shareholder returns for now.
Given its small-cap characteristics, it should also be considered that valuation multiples can swing relatively widely with changes in trading volume and supply-demand conditions. Whether the profit recovery continues to offset the revenue decline will likely be an important point to watch for future valuation.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-24
Owners' net profit expanded from a loss of KRW -37.36bn in 2023 to KRW 5.08bn in 2024 and KRW 15.66bn in 2025, with operating profit also improving in both 2026Q1 and 2026Q2. The debt ratio likewise fell sharply from 299.0% in 2023 to 43.0% in 2025, strengthening financial stability.
This combined improvement in earnings and balance sheet can be interpreted as a result of business efficiency gains.
The sales foundation built by supplying specialty products such as antifungals and urology drugs to clinic-level markets in dermatology, urology, and ENT serves as a stable revenue source.
In hair-loss treatment, the company directly produces minoxidil-based products and is expanding into the cosmeceutical market via its clinic channel. This channel competitiveness is an asset that can also be leveraged when new pipeline products are introduced.
If affiliate JW Pharmaceutical's Wnt-targeted hair-loss drug candidate 'JW0061' succeeds in commercialization, a role division is expected in which JW Pharmaceutical handles hospital-level sales while JW Shinyak manages co-marketing in clinic-level markets.
The two companies already have a collaboration framework through co-marketing of original products such as Livalo. However, this remains a long-term possibility contingent on a candidate still at an early development stage.
Consolidated revenue declined for three straight years, from KRW 104.2bn in 2023 to KRW 93.0bn in 2024 and KRW 81.0bn in 2025. Given a business structure with a high share of generics, the company is exposed to policy variables such as drug-price cuts, making top-line recovery a key question. It remains uncertain how long profit improvement can continue to offset the revenue decline.
Operating profit slowed sharply from KRW 2.70bn in 2025Q3 to KRW 1.42bn in 2025Q4 before improving again in 2026Q1 and 2026Q2, showing notable quarter-to-quarter swings. Owners' net profit also fluctuated more than operating profit, suggesting a meaningful influence from non-operating items. This volatility is a point worth noting when interpreting the earnings trend.
As a small-cap stock with a relatively small market capitalization, supply-demand dynamics can react sensitively to changes in trading volume. Given the characteristics of a stock with relatively low liquidity, caution is warranted in interpreting metrics beyond the share price itself. This is a market-structural factor that exists separately from the company's individual fundamentals.
Product categories with a high share of generics, such as antifungals and urology drugs, are continuously exposed to government drug-price cuts and price competition among rivals. This can act as a persistent pressure factor on revenue and margins. The three consecutive years of revenue decline appear related to this structural backdrop.
The large net loss in 2023 is presumed to reflect a valuation change in investment assets including R&D-related subsidiaries, and the subsequent balance-sheet recovery does not guarantee similar factors will not recur.
R&D investments such as CAR-M and CAR-NK cell therapy research through subsidiary JW Creagene are an area with uncertain outcomes. Whether related assets face impairment going forward will need continuous confirmation through disclosures.
The company has a history of issuing bonus shares on January 1 each year since 2021, which could be viewed positively from a shareholder-value perspective but requires care in interpreting metrics affected by changes in shares outstanding.
There have also been past instances of convertible bond conversion, meaning potential share-count increase factors persist. Such changes in capital structure can affect the continuity of per-share metric interpretation.
Check the 2026Q3 earnings disclosure to see whether the quarterly improvement trend in revenue and operating profit continues.
It is worth checking via disclosure whether the annual bonus-share issuance pattern repeated since 2021 continues into 2027.
Monitor disclosures on the clinical/development progress of affiliate JW Pharmaceutical's hair-loss drug candidate 'JW0061' to gauge how concretely the group synergy possibility is materializing.
Track further progress on subsidiary JW Creagene's joint CAR-M/CAR-NK cell therapy research with KURE.AI through future disclosures.
Continuously check quarterly revenue figures for changes in generic drug pricing policy and whether the revenue decline trend persists.
JW Shinyak is a company where owners' net profit turned from a large loss in 2023 to a clear and expanding surplus in 2024 and 2025, even as revenue declined for three consecutive years from 2023 to 2025. Financial stability also improved as the debt ratio fell sharply from 299.0% to 43.0% and equity was rebuilt.
Over the trailing four quarters (2025Q3-2026Q2), revenue rose modestly and operating profit improved for two consecutive quarters following a trough in 2025Q4.
However, whether this improvement can offset the annual revenue decline trend will require confirmation from additional quarters, and the wider swings in quarterly net profit relative to operating profit mean non-operating factors also warrant attention.
The clinic-specialized sales network and potential linkage to affiliate JW Pharmaceutical's new pipeline (including JW0061) are long-term points to watch, though it should be considered that the program remains at an early development stage.
Overall, the company appears to face a combination of positive changes—profit recovery and balance-sheet improvement—alongside challenges of revenue contraction and quarterly volatility.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.